Princess Margaret Cancer Center

PTC Therapeutics’ cancer stem cell program targeting BMI1 enters phase I

Thursday, April 30, 2015

PTC Therapeutics has announced that its oncology program targeting BMI1, a protein linked to drug-resistant cancers, has entered a phase I study in patients with advanced solid tumors. The open-label, first-in-human study will investigate the safety and pharmacokinetics of PTC596, an orally available small molecule. PTC’s BMI1 program is supported by a collaboration with the Wellcome Trust.

[Read More]

GSK launches global consortium with six cancer research centers

Friday, December 6, 2013

GlaxoSmithKline has formed the Oncology Clinical and Translational Consortium (OCTC), a collaborative scientific research network comprised of six international cancer centers. The centers include Gustave Roussy (Villejuif, France), University of TexasMD Anderson Cancer Center (Houston), Memorial Sloan-Kettering Cancer Center (New York), Netherlands Cancer Institute, Princess Margaret Cancer Center, University Health Network (Toronto, Canada) and Vall d’Hebron Institute of Oncology-VHIO (Barcelona, Spain). 

[Read More]